Implantable devices, like cardiac pacemakers and artificial hip replacements, offer substantial benefits but can also pose serious risks. Against this backdrop of potential risk--and, in some cases, inadequate regulation--this Insight on the Issues focuses on the Food and Drug Administration's oversight of implantable devices and suggests reform options to help improve the existing regulatory framework. A second Insight on the Issues deals with the lack of price transparency and the need for greater competition in the marketplace for implantable devices.
Reproduced with permission of the copyright holder. Further use of the material is subject to CC BY-NC-ND license. (More information)